Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone plus capecitabine for anthracycline/taxane non-responsive HER2-negative locally advanced breast cancer
ChiCTR2300069145Phase 4Recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of utidelone and capecitabine in breast cancer, sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: clinical response rate and events free survival. Started Mar 2023; status: recruiting.
02
Drugs
utidelonecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2300069145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069145.